Vicus Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $611K | Buy |
4,383
+663
| +18% | +$92.8K | 0.04% | 164 |
|
|
2025
Q4 | $457K | Sell |
3,720
-66
| -2% | -$8.02K | 0.03% | 187 |
|
|
2025
Q3 | $420K | Buy |
3,786
+52
| +1% | +$5.91K | 0.03% | 193 |
|
|
2025
Q2 | $414K | Sell |
3,734
-671
| -15% | -$71.4K | 0.03% | 175 |
|
|
2025
Q1 | $494K | Buy |
4,405
+83
| +2% | +$8.56K | 0.05% | 137 |
|
|
2024
Q4 | $399K | Sell |
4,322
-53
| -1% | -$4.77K | 0.04% | 156 |
|
|
2024
Q3 | $367K | Sell |
4,375
-1,431
| -25% | -$109K | 0.03% | 161 |
|
|
2024
Q2 | $398K | Sell |
5,806
-505
| -8% | -$33.7K | 0.04% | 188 |
|
|
2024
Q1 | $462K | Buy |
6,311
+1,490
| +31% | +$115K | 0.04% | 158 |
|
|
2023
Q4 | $391K | Sell |
4,821
-1,007
| -17% | -$78.4K | 0.04% | 149 |
|
|
2023
Q3 | $437K | Buy |
5,828
+720
| +14% | +$55.4K | 0.05% | 160 |
|
|
2023
Q2 | $394K | Buy |
5,108
+1,396
| +38% | +$111K | 0.04% | 150 |
|
|
2023
Q1 | $308K | Sell |
3,712
-285
| -7% | -$23.6K | 0.03% | 164 |
|
|
2022
Q4 | $343K | Sell |
3,997
-192
| -5% | -$15.2K | 0.04% | 148 |
|
|
2022
Q3 | $258K | Buy |
4,189
+480
| +13% | +$30.3K | 0.03% | 179 |
|
|
2022
Q2 | $229K | Buy |
3,709
+231
| +7% | +$14.3K | 0.03% | 198 |
|
|
2022
Q1 | $207K | Buy |
3,478
+268
| +8% | +$17.1K | 0.02% | 218 |
|
|
2021
Q4 | $210K | Buy |
+3,210
| New | +$221K | 0.02% | 220 |
|
|
2021
Q3 | – | Sell |
-3,252
| Closed | -$224K | – | 145 |
|
|
2021
Q2 | $224K | Sell |
3,252
-338
| -9% | -$22.6K | 0.04% | 139 |
|
|
2021
Q1 | $232K | Buy |
+3,590
| New | +$231K | 0.03% | 211 |
|
|
2020
Q4 | – | Sell |
-4,819
| Closed | -$305K | – | 232 |
|
|
2020
Q3 | $305K | Sell |
4,819
-1,858
| -28% | -$129K | 0.04% | 164 |
|
|
2020
Q2 | $514K | Buy |
6,677
+1,003
| +18% | +$76.9K | 0.08% | 119 |
|
|
2020
Q1 | $424K | Sell |
5,674
-876
| -13% | -$60.5K | 0.08% | 118 |
|
|
2019
Q4 | $426K | Sell |
6,550
-568
| -8% | -$37K | 0.06% | 139 |
|
|
2019
Q3 | $451K | Sell |
7,118
-733
| -9% | -$47.9K | 0.06% | 161 |
|
|
2019
Q2 | $530K | Sell |
7,851
-369
| -4% | -$24.3K | 0.07% | 145 |
|
|
2019
Q1 | $534K | Buy |
8,220
+351
| +4% | +$23.3K | 0.08% | 137 |
|
|
2018
Q4 | $492K | Sell |
7,869
-67
| -0.8% | -$4.68K | 0.09% | 142 |
|
|
2018
Q3 | $613K | Sell |
7,936
-64
| -0.8% | -$4.83K | 0.1% | 133 |
|
|
2018
Q2 | $567K | Sell |
8,000
-2,547
| -24% | -$180K | 0.09% | 137 |
|
|
2018
Q1 | $795K | Sell |
10,547
-675
| -6% | -$53.7K | 0.14% | 114 |
|
|
2017
Q4 | $804K | Sell |
11,222
-274
| -2% | -$20.8K | 0.14% | 113 |
|
|
2017
Q3 | $931K | Buy |
11,496
+2,751
| +31% | +$210K | 0.18% | 96 |
|
|
2017
Q2 | $619K | Buy |
8,745
+983
| +13% | +$65.4K | 0.13% | 127 |
|
|
2017
Q1 | $527K | Buy |
7,762
+1,321
| +21% | +$92.9K | 0.11% | 142 |
|
|
2016
Q4 | $461K | Buy |
6,441
+1,758
| +38% | +$131K | 0.1% | 146 |
|
|
2016
Q3 | $371K | Buy |
4,683
+748
| +19% | +$60.8K | 0.08% | 158 |
|
|
2016
Q2 | $328K | Buy |
3,935
+776
| +25% | +$68.9K | 0.08% | 143 |
|
|
2016
Q1 | $290K | Buy |
3,159
+891
| +39% | +$80.3K | 0.07% | 148 |
|
|
2015
Q4 | $229K | Buy |
+2,268
| New | +$236K | 0.06% | 175 |
|
Other funds holding GILD
VCM
VPM
Vicus Capital's GILD Position: Q1 2026 in Review
Vicus Capital increased its Gilead Sciences (GILD) stake by 18% in Q1 2026, buying an estimated $92.8K and bringing the position to 4,383 shares worth $611K. The position accounts for 0.04% of the portfolio, ranked #164.
Vicus Capital first reported a position in GILD in Q4 2015 and has held it in 40 quarters since. The position peaked at $931K in Q3 2017. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Vicus Capital held 4,383 shares of Gilead Sciences worth $611K as of Q1 2026.
- Vicus Capital bought 663 Gilead Sciences shares in Q1 2026, an estimated $92.8K.
- Gilead Sciences made up 0.04% of Vicus Capital's portfolio in Q1 2026, its #164 holding.
- Vicus Capital first reported a position in Gilead Sciences in Q4 2015 and has held it in 40 quarters since.
- Vicus Capital's Gilead Sciences position peaked at $931K in Q3 2017.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Vicus Capital's 13F filing for Q1 2026, filed 22 Apr 2026.